Will you offer olaparib + abiraterone for all patients with metastatic castrate resistant prostate cancer based on results of PROPEL trial?

Do you find the ibPFS endpoint sufficient to change practice for any or all patients, or will you await OS or other data/trials?

Answer from: Medical Oncologist at Academic Institution

PROpel is clearly positive for its primary endpoint of delaying rPFS significantly in ALL first line mCRPC patients above and beyond abiraterone and prednisone alone. The delay of 8-10 months over an active comparator is significant both statistically and clinically, and is similar to the improvemen...

Comments

Medical Oncologist at Florida Cancer Specialists
Did PROpel include patients who have been treated ...

Medical Oncologist at Carle Illinois College of Medicine
In PROpel, about 24% of patients had received prio...

Answer from: Medical Oncologist at Community Practice

Not at this point. The trial results were interesting, but I am waiting for information as the data mature and more correlative work is done. (Honestly, I do not know what is being done at this point.)

Please select the option that best describes you:

Will you offer olaparib + abiraterone for all patients with metastatic castrate resistant prostate cancer based on results of PROPEL trial?

Related Questions